Zobrazeno 1 - 2
of 2
pro vyhledávání: '"Norihiko Oharu"'
Autor:
Norihiko Oharu, Patrick Schnell, Keith D. Wilner, Jack Mardekian, Michelle Yu-Kite, Diane D. Wang, Jillian Motyl Rockland, Dongrui R. Lu, Todd VanArsdale, Jennifer M. Tursi, Albert L. Kraus, Cynthia Huang Bartlett, Matthew J. Cotter, Kenneth R. Carson, Jaclyn Decembrino, Sindy T. Kim, Anala Gossai, Tamara Snow
Publikováno v:
Clinical Pharmacology & Therapeutics. 111:302-309
This report examined the benefits and risks of palbociclib plus endocrine therapy (ET) in men with hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (MBC). Palbociclib was evaluated usi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::bd161687b72b981353a6643c01b43925
https://doi.org/10.1002/cpt.2454
https://doi.org/10.1002/cpt.2454
Autor:
Albert L. Kraus, Kenneth R. Carson, Cynthia Huang Bartlett, Jack Mardekian, Jillian Motyl Rockland, Dongrui (Ray) Lu, Patrick Schnell, Tamara Snow, Jaclyn Decembrino, Sindy T. Kim, Michelle Yu-Kite, Matthew J. Cotter, Norihiko Oharu, Keith D. Wilner, Jennifer M. Tursi
Publikováno v:
Journal of Clinical Oncology. 37:1055-1055
1055 Background: The rarity of BC in men limits the feasibility of randomized clinical studies in this population. Treatment guidelines recommend that men with BC be treated similarly to postmenopausal women. PAL, a cyclin-dependent kinase 4/6 inhibi
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::f6a0182c2ad92c3b14ebac6edb83673e
https://doi.org/10.1200/jco.2019.37.15_suppl.1055
https://doi.org/10.1200/jco.2019.37.15_suppl.1055